key: cord-0868610-eemrgi8j authors: Gorder, Kari; Young, Wesley; Kapur, Navin K.; Henry, Timothy D.; Garcia, Santiago; Guddeti, Raviteja R.; Smith, Timothy D. title: Mechanical Circulatory Support in COVID-19 date: 2022-03-25 journal: Cardiol Clin DOI: 10.1016/j.ccl.2022.03.003 sha: 4f61d4f781b125db6e24a8337576727d7c487923 doc_id: 868610 cord_uid: eemrgi8j Despite aggressive care, patients with cardiopulmonary failure and COVID-19 experience unacceptably high mortality rates. The use of mechanical circulatory support devices in this population offers potential benefits but confers significant morbidity and novel challenges for the clinician. Thoughtful application of this complex technology is of the utmost importance and should be done in a multidisciplinary fashion by teams familiar with mechanical support devices and aware of the particular challenges provided by this complex patient population. approach to the application of this technology remains challenging, partially due to the inherent difficulties with randomized controlled trials in this heterogenous and complex patient population. [4, 5] However, observational and cohort data from several institutions have shown the utility of the thoughtful application of MCS technology based on objective criteria, invasive monitoring devices and a multidisciplinary shock team approach. [6, 7] The range and diversity of MCS devices has ushered in a new era for patients with CS, but recently clinicians have been faced with a new challenge: a global pandemic. Coronavirus disease 2019 (COVID-19) has challenged our understanding of cardiopulmonary physiology and brought with it unique challenges in a resource-limited environment. While the primary effect of COVID-19 is on the respiratory system, its deleterious consequences have the potential to reach across all organ systems and can adversely affect cardiac function. This review article will focus on our current understanding of the effects of COVID-19 in the adult population as it pertains to CS, the assessment and evaluation of these patients, and the implementation of MCS in patients with cardiac or pulmonary failure, to include both veno-arterial (VA) and veno-venous (VV) ECMO. The results of the North American COVID-19 ST-Segment Elevation Myocardial Infarction (NACMI) registry were even more sobering: COVID-19 patients presenting with a STEMI experienced a 33% mortality rate, compared to 4% seen in non-COVID-19 controls, with a significantly increased rate of CS at 18%. [ For COVID-19 patients suffering from myocardial infarction, the limited data available suggest a significantly increased mortality rate, especially for those who require some type of MCS. Data from the NACMI registry showed an almost 60% mortality rate in COVID-19 positive STEMI patients who required MCS, compared to a 30% mortality rate in non-COVID STEMI patients on MCS. [26] In this registry, 13% of COVID-19 positive STEMI patients received MCS, similar to rates seen in the non-COVID-19 population, highlighting the significant increase in mortality that a concomitant COVID-19 infection conferred. Within the COVID-19 group, the most prevalent type of MCS was the IABP (62%), followed by Impella (28%) and ECMO (7%). Data for or against a particular MCS strategy is limited by the lack of high-quality evidence in the CS patient population. While the IABP remains commonly used for CS patients requiring MCS, longitudinal data has confirmed that these devices do not confer a mortality benefit. [27] Percutaneous left ventricular assist devices such as the Impella have shown some improvement in small clinical trials and registry data, although the evidence remains mixed and definitive research is ongoing. [28] For these strategies in COVID-19 patients, the data is even more scarce. Case J o u r n a l P r e -p r o o f reports exist of using IABPs or Impellas to support hemodynamics in patients with COVID-19 and CS, with mixed outcomes. [12, 29] VA ECMO for cardiovascular collapse in the COVID-19 population represents the maximal level of support possible and brings with it a high rate of morbidity and mortality -so high, perhaps, that many centers may not offer it in this patient population. Indeed, the Overall, data on outcomes for patients with COVID-19 requiring VA ECMO for cardiogenic shock is extremely limited. [31] A large retrospective review of ELSO data found that VA ECMO represents a significant minority of all COVID-19 ECMO cases, perhaps as low as 4%, but is associated with a significantly higher in-hospital mortality rate compared to COVID-19 patients on VV ECMO. [32] ELSO itself does not directly report COVID-19 VA ECMO survival on its public dashboard, but at the time of publication, the survival rate to discharge in the COVID-19 non-ARDS adult cohort is less than 10%. The remainder of our current data is limited to case series and case reports, most of which report significant mortality rates for VA ECMO in COVID-19, far above pre-pandemic benchmarks. [35] While more information is certainly needed about this patient population in order to guide thoughtful application and patient selection, it can be said that mortality rates for COVID-19 patients requiring any degree of MCS are high, and VA ECMO portends an even higher risk of death. Centers and clinicians who choose to pursue any MCS strategy in COVID-19 patients must do so thoughtfully and selectively, understanding the inherent risks and resources required. 19 related ARDS at the beginning of the pandemic, when initial data suggested an up to 97% 28day mortality rate for intubated COVID-19 patients. [38] After the first wave, some initial registry data was encouraging: mortality for COVID-19 patients on VV ECMO was less than 40%, which was in line with pre-pandemic outcomes. [32] However, much of that initial enthusiasm has been since tempered, as subsequent waves of the pandemic have shown diminishing returns from the application of VV ECMO in this patient population. Registry data revealed a significant increase in mortality as the pandemic has progressed: after May 2020, mortality for this cohort rose above 50%. [39] Although the underlying reasons for this decline remain somewhat unclear, the available evidence does suggest some possible etiologies. As the pandemic progressed, more centers with less overall ECMO experience began offering VV ECMO to COVID-19 patients. Registry data did show that hospitals with less ECMO experience witnessed higher mortality rates than more experienced ECMO centers,[39] potentially underscoring the challenges of expanding a complex technology to centers with less volume or training. A recent observational study showed an increased risk of mortality for patients cannulated at a non-specialized center. [40] Some centers applied a more aggressive strategy of earlier VV ECMO cannulation: one small retrospective study showed lower mortality rates with early VV ECMO use, and a significantly lower mortality rate of 25% for patients who were cannulated prior to intubation. [46] However, VV ECMO remains a technically challenging and personnel-intensive limited resource, with significant risks associated with its use, and clear guidelines on how and when to apply this technology to COVID-19 patients remains unclear. [47] Unfortunately, most of the data on VV ECMO during COVID-19 comes from retrospective studies, case series, and international registries which lack control groups or randomization, and are often subject to reporting bias. The heterogeneity between survivors and non-survivors of ARDS following COVID-19 is becoming clearer, but the scientific community continues to lack the ability to reliability predict which patients may benefit from VV ECMO and in what manner that technology should be applied. As the body of evidence in this patient population grows, institutions must remain flexible about applying clear inclusion criteria for these patients which reflect best-practices for VV ECMO but also take into consideration the resources of the institution or region, as this can significantly impact mortality rates as well. [40] Further studies are needed to focus on defining and identifying severe ARDS phenotypes to better assess the efficacy of such a resource-intensive technology as VV ECMO. The COVID-19 pandemic has significantly impacted almost all aspects of modern healthcare, including increased mortality rates for classically described disease processes. For patients with underlying cardiac disease, concomitant COVID-19 infection significantly increases morbidity and mortality and may precipitate conditions such as CS. While randomized controlled data is sorely lacking, retrospective evidence shows that patients with COVID-19 and CS are sicker and are more likely to die compared to traditional controls. Similarly, COVID-19 patients with isolated respiratory failure and ARDS seem to have increased challenges compared to historical outcomes. The application of MCS to this patient population remains technically complex and resource intensive, carrying with it a significant mortality rate. While the scientific community awaits more evidence-based practice guidelines for MCS for COVID-19 patients, the necessity of a thoughtful, multidisciplinary team approach to these challenging cases at high-volume, experienced centers remains of the utmost importance. Cardiogenic Shock Classification to Predict Mortality in the Cardiac 10 Myocardial injury and COVID-19: Possible mechanisms Acute myocardial injury in patients with COVID-19: Possible mechanisms and clinical implications COVID-19 patient with coronary thrombosis supported with ECMO and Impella 5.0 ventricular assist device: a case report Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection Myocarditis in COVID-19 presenting with cardiogenic shock: a case series Diagnosis-wide analysis of COVID-19 complications: an exposurecrossover study Spectrum of Cardiac Manifestations in COVID-19: A Systematic